Researchers say the gut microbiome may be a viable targetable biomarker to improve immunotherapy responses in those with glioblastoma and a range of other cancers.
Researchers have developed drug-carrying nanoparticles that cross the blood-brain barrier, allowing for more effective delivery to the brain than conventional medications. The nanoparticles can get into tumors and kill glioblastoma brain cancer cells.
Study reveals the ZNF117 gene is a major regulator of glioblastoma tumor cells.
INSR, a protein essential for insulin activity, plays a critical role in stem cell longevity. Additionally, inactivating INSR in glioblastoma brain cancer stem cells inhibits the growth of primitive tumor forming cells.
Variations in the TSPO neuroinflammation-associated protein's structure correlates with worse survival outcomes for male glioblastoma brain cancer patients than females.
A combination of approved and novel therapeutics improved survival rates and reduced both tumor volume and growth for those suffering from glioblastoma brain cancer.
Cellular reprogramming of glioma cells into neural cells may be a promising treatment for glioblastoma brain cancer.
Researchers have identified specific proteins that drive the development of cancer stem cells. They report targeting and suppressing galectin1, in addition to radiation therapy, could be an effective treatment for glioblastoma brain cancer.